Drug Discovery Technology using Human iPS Cells
Conference Recording Jan 04, 2013
About the Speaker
Dr. Yokoyama joined ReproCELL Inc. in 2004 as a general manager of business development and became Chief Executive Officer in 2005. He has been responsible for all aspects of new product management, alliance, and fund raising. He also participated in establishing a Stem Cell and Drug Discovery Institute in which human ES cell research is intensively carried out for the purpose of drug discovery and toxicity testing applications. From 1996 to 2004, he worked for McKinsey and Company Inc. as a management consultant and then for Sumitomo 3M, a subsidiary of 3M, to serve as a R&D leader of a new project. He received his Ph.D. in chemistry from Tokyo University in 1996.
Human iPS cell technology is expected to become a mainstream of drug discovery, which allows a mid-high throughput cell-based assay using human native cells derived from iPS cells. iPS cells can be expanded in vitro infinitely and then can be differentiated to various types of native cells including cardiomyocytes, neural cells, and hepatocytes, which means unlimited supply of human native cells in large scale. We succeeded in releasing to the market iPSC-derived cardiomyocytes in 2009 which can be applied for toxicity assay using MEA system and Ca imaging systems. In 2010, we launched iPSC-derived dopaminergic neurons which can be applied for Parkinson's disease assay. In addition, we have a plan to launch iPSC-derived hepatocytes in 2012. In this presentation, we would like to share updated information on three types of native cells and the assay technology.